GeneDx Holdings Corp. (WGS) Securities Class Action Lawsuit Update

• Company: GeneDx Holdings Corp. (NASDAQ: WGS)
• Lead Plaintiff Deadline: August 3, 2026
• Class Period: April 16, 2025 – May 4, 2026
• Stock Drop: May 5, 2026 – WGS fell $33.42 (49.20%) from a prior close of $67.93
• Lawsuit Type: Securities Class Action

Introduction

On June 4, 2026, a securities class action complaint was filed in the United States District Court for the District of Connecticut against GeneDx Holdings Corp. (NASDAQ: WGS), CEO Katherine Stueland, and CFO Kevin Feeley. The lawsuit was brought on behalf of all investors who purchased WGS common stock between April 16, 2025 and May 4, 2026, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

At the heart of the case is GeneDx's April 2025 agreement to acquire Fabric Genomics, an AI-driven genomic interpretation firm, in a deal worth up to $51 million; GeneDx later reported completing the acquisition for total consideration of $36.5 million. The complaint alleges that defendants promoted Fabric as a growth-driving acquisition that would expand GeneDx's addressable market, create scalable revenue streams, and improve financial performance. Over the months that followed, GeneDx's stock climbed to a Class Period high of $167.52 as management touted Fabric's integration progress, favorable margin dynamics, and ambitious revenue guidance of $540 to $555 million for 2026.

Then, after hours on May 4, 2026, the complaint alleges that GeneDx disclosed information that painted a sharply different picture. GeneDx reported first quarter 2026 results that missed revenue estimates across both its exome and genome lines, cut full-year guidance to $475 to $490 million from prior guidance of $540 to $555 million, revealed that adjusted gross margins had fallen from 74% to 69%, and disclosed a $31.2 million impairment charge directly attributable to Fabric. The stock cratered, falling $33.42 per share, or 49.20%, from its prior close of $67.93. According to the complaint, the rosy picture defendants painted throughout the Class Period lacked a reasonable factual basis, and investors paid the price.

Backdrop and Business Context

GeneDx traces its origins to 2000, when Dr. Sherri Bale and Dr. John Compton founded the company as an NIH spinout in Gaithersburg, Maryland, aiming to bridge the gap between advancing genomics research and the limited availability of clinical genetic testing for rare disorders. The company changed hands several times, acquired by BioReference Laboratories in 2006, folded into OPKO Health in 2015, and then purchased by Sema4 in May 2022 for approximately $623 million. In January 2023, Sema4 rebranded as GeneDx Holdings Corp. and began trading on the NASDAQ under the ticker WGS, signaling a strategic refocus on rare-disease genomic diagnostics.

GeneDx makes money primarily by performing high-complexity genetic tests, particularly whole exome sequencing and whole genome sequencing, for hospitals, health systems, and specialist physicians diagnosing pediatric and rare diseases. Revenue is generated on a test-by-test basis, with the vast majority reimbursed by commercial insurers and government payers. By 2025, exome and genome test revenue accounted for approximately $360 million of the company's roughly $427 million in total annual revenue. The company also operates a smaller biopharma data and services business, leveraging its GeneDx Infinity dataset of nearly one million clinical exomes and genomes to support drug discovery and clinical trial design for pharmaceutical partners.

GeneDx operates in the clinical genomic diagnostics market, with a niche focus on rare and pediatric disease. The company employs approximately 1,000 people and is headquartered in Stamford, Connecticut, with its primary clinical laboratory in Gaithersburg, Maryland. According to the complaint, despite the outward trajectory of growth, defendants knew of or recklessly disregarded significant problems with the Fabric Genomics acquisition that would ultimately drag the company's financials down.

Promises Made vs. Reality

The story defendants told investors began on April 16, 2025, when GeneDx announced its agreement to acquire Fabric Genomics. In the press release unveiling the deal, the Company proclaimed that the acquisition would expand GeneDx's addressable market with "multiple scalable revenue streams," and characterized Fabric's software as a platform that "transforms static data into a dynamic, recurring revenue-generating platform-driving growth through software margins and high-leverage interpretation services across geographies and clinical use cases." When the deal closed weeks later, CEO Stueland reinforced the message, telling investors the acquisition would "unlock recurring software-based revenue streams through Fabric's interpretation as-a-service model."

As the months progressed, management's enthusiasm only intensified. During the Q2 2025 Earnings Call on July 29, 2025, Stueland described Fabric as a competitive weapon, stating that GeneDx's lead would "only continue to expand" as Fabric's proprietary algorithms were integrated into the core platform. CFO Feeley echoed the optimism, telling investors "there was room to run in terms of reducing COGS in the future by combining the best of capability between GeneDx and Fabric." Stueland went further during the Q&A session, assuring listeners that Fabric was "off to a great start," that its teams were "on track with our plan this year in terms of their revenues, their gross margins," and that the company had already begun hiring international sales representatives to drive Fabric's utilization globally. By October 2025, Feeley pointed to adjusted gross margins of 74%, driven by favorable mix dynamics, and cited an average reimbursement rate above $3,800.

The bullish narrative carried into 2026. On January 14, 2026, Stueland described Fabric as a vehicle for global scale, explaining that "wherever there is a sequencer being bought anywhere in the world, we can put that interpretation platform and that centralized intelligence on top of it." She reiterated revenue guidance of $540 to $555 million for the year, with 33% to 35% growth and adjusted gross margins of at least 70%. During the Q4 2025 Earnings Call on February 23, 2026, Feeley acknowledged that mix dynamics had "fluctuated some" and that the average reimbursement rate had dipped to approximately $3,750, but he reassured investors that "the long-term trend is up and durable" and described the company's gross margin guidance as "a fairly conservative view."

Then, according to the complaint, after hours on May 4, 2026, GeneDx disclosed information that allegedly revealed the problems with Fabric and the Company's financial outlook. GeneDx disclosed first quarter 2026 results revealing that the Company had missed revenue estimates for both its exome and genome lines. Stueland stated, according to the complaint, that "it had become increasingly clear that Fabric was best suited only for international markets," that the Company had "much left to do" to integrate Fabric, and that the Company was lowering its expectations for Fabric's revenue contribution. The blended average reimbursement rate had plummeted to approximately $3,300, down roughly $500 from only two quarters prior. Adjusted gross margins fell from 74% to 69%. Most strikingly, GeneDx disclosed a $31.2 million impairment loss directly attributable to Fabric, writing down goodwill and other Fabric intangible assets. Full-year revenue guidance was cut to $475 to $490 million, down from prior guidance of $540 to $555 million.

As alleged in the complaint, the statements defendants made throughout the Class Period about Fabric's viability, its integration progress, its contribution to margins and revenue growth, and the Company's resulting financial outlook were materially false and misleading. Defendants knew of, or recklessly disregarded, significant problems with Fabric that would negatively impact GeneDx's overall business, yet they continued to present Fabric as a growth-driving, on-track acquisition, while the stock traded at artificially inflated prices.

Timeline of Alleged Misconduct and Disclosures

Class Period: April 16, 2025 -- May 4, 2026, inclusive.

April 16, 2025: Class Period opens. GeneDx announces agreement to acquire Fabric Genomics for up to $51 million. Press release states the acquisition will expand the addressable market with "multiple scalable revenue streams" and that Fabric's software "transforms static data into a dynamic, recurring revenue-generating platform."

May 5, 2025: GeneDx announces completion of the Fabric acquisition. CEO Stueland states the deal will "unlock recurring software-based revenue streams through Fabric's interpretation as-a-service model."

July 29, 2025: Q2 2025 Earnings Call. CEO Stueland states GeneDx's lead will "only continue to expand" as Fabric is integrated. CFO Feeley says there is "room to run in terms of reducing COGS" by combining GeneDx and Fabric capabilities. Stueland adds that Fabric is "off to a great start" and "on track" with revenue and gross margin plans.

October 28, 2025: Q3 2025 Earnings Call. CFO Feeley reports adjusted gross margin of 74%, driven by favorable mix shift, and an average reimbursement rate above $3,800.

January 12, 2026: GeneDx announces preliminary 2025 financial results and provides 2026 guidance of $540 to $555 million in revenue.

January 14, 2026: Industry call. CEO Stueland discusses how Fabric will help GeneDx scale globally, stating the interpretation platform can be deployed "wherever there is a sequencer being bought anywhere in the world." Stueland reiterates revenue guidance of $540 to $555 million with adjusted gross margins of at least 70%.

February 23, 2026: Q4 2025 Earnings Call and 10-K filing. CFO Feeley notes mix dynamics "fluctuated some" and reimbursement rate of approximately $3,750, but states "the long-term trend is up and durable" and characterizes gross margin guidance as "a fairly conservative view." Company reports Fabric acquisition total consideration of $36.5 million including $3.4 million in contingent consideration.

May 4, 2026 (after hours): Alleged corrective disclosure. GeneDx reports Q1 2026 results revealing missed revenue estimates for exome and genome lines. Full-year revenue guidance was cut to $475 to $490 million, down from prior guidance of $540 to $555 million. Adjusted gross margin falls to 69% from 74%. Blended average reimbursement rate drops to approximately $3,300. Company discloses $31.2 million impairment loss attributable to Fabric. CEO Stueland states, according to the complaint, that Fabric is best suited only for international markets and the Company has "much left to do" to integrate it.

May 5, 2026: WGS stock declines $33.42 per share, or 49.20%, from a prior close of $67.93.

Investor Harm and Market Reaction

According to the complaint, the May 4, 2026 disclosures caused WGS shares to fall sharply the next trading day. WGS shares, which had closed at $67.93 on the trading day before the after-hours announcement, fell $33.42 per share, a decline of 49.20%. Nearly half the stock's value evaporated in a single session as the market digested the simultaneous miss on exome and genome revenue, the reduction in full-year guidance, the margin compression, and the $31.2 million Fabric impairment charge.

The scale of the decline was striking when measured against the Class Period trajectory. During the period in which defendants promoted Fabric's potential and guided to aggressive growth targets, WGS stock had risen to a Class Period high of $167.52. The post-disclosure price represented a fraction of that peak. As Canaccord Genuity analyst Kyle Mikson wrote in a report following the May 4 disclosures, GeneDx's results "appeared to reflect the reversal of important growth drivers" and the problems appeared "more systemic in nature," raising questions about when the company's core business would recover to historical growth rates.

The complaint alleges that investors who purchased WGS common stock during the Class Period suffered significant losses after the alleged truth was revealed. The complaint alleges that these losses were directly and proximately caused by defendants' materially false and misleading statements and omissions throughout the Class Period.

Litigation & Procedural Posture

The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against GeneDx Holdings Corp. and the Individual Defendants (Stueland and Feeley), as well as claims under Section 20(a) of the Exchange Act against the Individual Defendants as controlling persons of the Company.

The defendants are GeneDx Holdings Corp., CEO Katherine Stueland, and CFO Kevin Feeley.

Scienter allegations center on the Individual Defendants' positions as CEO and CFO, which afforded them the power and authority to control the contents of the Company's SEC reports, press releases, and presentations to analysts and investors. According to the complaint, both Individual Defendants were provided with copies of the Company's reports and press releases prior to or shortly after their issuance and had the ability and opportunity to prevent their issuance or cause them to be corrected. The complaint alleges that by virtue of their positions and access to material non-public information, defendants knew that the adverse facts regarding Fabric had not been disclosed to the public and that the positive representations being made were materially false or misleading. No insider sales or confidential witness evidence is specifically detailed in the complaint.

Procedurally, the case was filed on June 4, 2026 in the United States District Court for the District of Connecticut. The complaint seeks class certification under Rule 23 of the Federal Rules of Civil Procedure on behalf of all persons or entities that purchased WGS common stock during the April 16, 2025 to May 4, 2026 Class Period. As of May 20, 2026, WGS had over 29.69 million shares of common stock outstanding. The lead plaintiff deadline is August 3, 2026.

SEC Filings & Risk Factors

The complaint identifies a pattern of disclosure throughout the Class Period in which GeneDx's public statements, earnings calls, and SEC filings consistently portrayed the Fabric acquisition as a strategic success and the Company's financial trajectory as robust, while allegedly failing to disclose material adverse facts about Fabric's viability and its drag on the Company's operations.

The Company's Annual Report on Form 10-K, filed on February 23, 2026 for fiscal year 2025, disclosed that GeneDx completed the Fabric acquisition for total consideration of $36.5 million, including $3.4 million in contingent consideration, and noted a net increase of $0.6 million in goodwill. The filing reported continued improvement in gross margins, which grew from 45% in FY 2023 to 65% in FY 2024 to 71% in FY 2025. However, the complaint alleges that this filing failed to disclose known problems with Fabric's integration and viability that were already impacting the business.

On the Q3 2025 Earnings Call on October 28, 2025, CFO Feeley highlighted that adjusted gross margin had reached 74%, driven by favorable mix shift, and cited average reimbursement rates above $3,800. By the Q4 2025 Earnings Call on February 23, 2026, the narrative had begun to subtly shift: Feeley acknowledged that mix dynamics had "fluctuated some" and that the average reimbursement rate had declined to approximately $3,750. Nevertheless, he characterized the long-term trend as "up and durable" and described the Company's gross margin guidance as "a fairly conservative view." The complaint alleges these characterizations were misleading given the trajectory that would be revealed just months later.

The alleged corrective disclosures, including the Company's Q1 2026 Form 10-Q, earnings press release, and earnings call, painted a starkly different picture. Adjusted gross margins had fallen to 69%, the blended average reimbursement rate had dropped to approximately $3,300 (down from $3,800 just two quarters earlier), full-year revenue guidance was cut by 15% to $475 to $490 million, and the Company recorded a $31.2 million impairment loss directly attributable to Fabric. The complaint alleges this before-and-after contrast demonstrates that defendants' prior characterizations of Fabric's progress, the Company's margin trajectory, and its revenue outlook lacked a reasonable factual basis.

The overall pattern alleged in the complaint is one of sustained optimism regarding a high-profile acquisition coupled with consistent failure to disclose known material risks and integration problems. Defendants allegedly presented Fabric as a growth catalyst delivering recurring revenue streams and cost synergies, while the complaint alleges that Fabric had failed to meet its goals and was instead dragging the Company’s financials down. The complaint points to the $31.2 million impairment charge as evidence of the alleged gap between defendants' prior statements and the underlying condition of the Fabric acquisition.

How to Join the GeneDx Holdings (WGS) Class Action

• Confirm you purchased WGS shares during the April 16, 2025 to May 4, 2026 class period
• Review the allegations and eligibility requirements in the pending securities class action
• Gather trade confirmations and brokerage records documenting purchases or losses
• Consult counsel regarding lead plaintiff deadlines, eligibility, and recovery rights
• Click here to check eligibility

Disclaimer: Attorney Advertising. This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.